MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.intimp.2026.116678

Медицинская библиотека · International immunopharmacology · 2026

SB290157, a selective complement C3a receptor antagonist, ameliorates aortic dissection by suppressing inflammatory signaling pathways to attenuate aortic wall inflammation and structural damage.

Huang Yutao, Ji Hongyan, Li Hongliang, Mu Tong, Lu Xin, Liu Qi, Yang Junyi, Liu Xudong, Chen Jing

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Aortic dissection (AD) is a life-threatening cardiovascular disease characterized by high mortality and a lack of effective pharmacotherapies. C3a, a complement C3 cleavage product, is critical for immunity, and co-inhibition of C3a and C5a prevents aortic aneurysm. However, whether and how single C3a activity inhibition alleviates AD remains unclear.

METHODS

Levels of C3a, IL-6, C3 and NF-κB levels were compared between aortic samples from healthy individuals and AD patients. SB290157 (a C3aR antagonist) was administered to BAPN/Ang II-induced AD mice, where aortic lesions, survival, signaling pathways, cytokines and T lymphocyte subsets were assessed. Functional assays and phenotypic characterization were performed in MOVAS cells, and molecular docking and molecular dynamics simulations were conducted to analyze SB290157-C3aR interactions.

RESULTS

AD patients exhibited significantly elevated C3a, IL-6, C3, and NF-κB levels, with male gender and hypertension identified as clinical risk factors for AD. The elevated cytokine and complement levels were recapitulated in mice. SB290157 alleviated aortic injury, improved survival, reduced pro-inflammatory factors, inhibited TLR4/NF-κB signaling, modulated T subsets, and preserved vascular smooth muscle integrity. In MOVAS cells, it suppressed inflammation, migration, and the synthetic phenotype, induced moderate dose-dependent apoptosis, and bound strongly to C3aR (8ZWF structure) with optimal binding parameters.

CONCLUSION

SB290157 exerts anti-AD effects likely by modulating the C3a/C3aR axis, thereby mitigating C3a-mediated immunoinflammation and preserving the contractile phenotype of aortic smooth muscle cells. However, high-dose SB290157 (above 50 nM) may induce non-selective apoptosis in MOVAS cells, representing potential risks for therapeutic application.

Для цитирования: Huang Yutao, Ji Hongyan, Li Hongliang, Mu Tong, Lu Xin, Liu Qi, Yang Junyi, Liu Xudong, Chen Jing. SB290157, a selective complement C3a receptor antagonist, ameliorates aortic dissection by suppressing inflammatory signaling pathways to attenuate aortic wall inflammation and structural damage.. International immunopharmacology. 2026. DOI: 10.1016/j.intimp.2026.116678.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.